Table 3.
Clinical and Histological Characteristics for those with and without somatic BRCA1 or BRCA2 PSVs
| Somatic BRCA1 or BCRA2 | ||||
|---|---|---|---|---|
| No (N = 72) | Yes (N = 15) | |||
| n | % | n | % | |
| Age at diagnosis | ||||
| Mean ± SD | 51.90 | 12.10 | 55.73 | 9.95 |
| Median (Q1-Q3) | 51.50 | 44.50-60.0 | 56.00 | 47.0-64.0 |
| Family History | ||||
| Yes | 7 | 9.7% | 2 | 13.3% |
| No | 65 | 90.3% | 13 | 86.7% |
| Laterality | ||||
| Bilateral | 56 | 77.8% | 10 | 66.7% |
| Unilateral | 16 | 22.2% | 5 | 33.3% |
| Allele | ||||
| Not Wild | 17 | 23.6% | 12 | 80.0% |
| Wild | 55 | 76.4% | 3 | 20.0% |
| Stage at Diagnosis | ||||
| Unknown | 4 | 5.6% | 0 | 0.0% |
| 0 | 1 | 1.4% | 1 | 6.7% |
| I | 13 | 18.1% | 3 | 20.0% |
| IIA | 4 | 5.6% | 2 | 13.3% |
| IIB | 4 | 5.6% | 1 | 6.7% |
| IIIA | 6 | 8.3% | 1 | 6.7% |
| IIIC | 26 | 36.1% | 5 | 33.3% |
| IV | 14 | 19.4% | 2 | 13.3% |
| Tumor stage | ||||
| Unknown | 4 | 5.6% | 0 | 0.0% |
| Tis | 1 | 1.4% | 0 | 0.0% |
| T1a | 4 | 5.6% | 0 | 0.0% |
| T1b | 1 | 1.4% | 0 | 0.0% |
| T1c | 9 | 12.5% | 3 | 20.0% |
| T2a | 4 | 5.6% | 1 | 6.7% |
| T2b | 5 | 6.9% | 0 | 0.0% |
| T2c | 1 | 1.4% | 1 | 6.7% |
| T3a | 11 | 15.3% | 4 | 26.7% |
| T3b | 3 | 4.2% | 1 | 6.7% |
| T3c | 24 | 33.3% | 4 | 26.7% |
| Tx | 5 | 6.9% | 1 | 6.7% |
| Node stage | ||||
| Unknown | 4 | 5.6% | 0 | 0.0% |
| N0 | 17 | 23.6% | 2 | 13.3% |
| N1 | 8 | 11.1% | 4 | 26.7% |
| Nx | 43 | 59.7% | 9 | 60.0% |
| Metastatic stage | ||||
| Unknown | 4 | 5.6% | 0 | 0.0% |
| M0 | 25 | 34.7% | 5 | 33.3% |
| M1 | 6 | 8.3% | 2 | 13.3% |
| Mx | 37 | 51.4% | 8 | 53.3% |
| FIGO classification | ||||
| IA | 3 | 4.2% | 0 | 0.0% |
| IB | 0 | 0.0% | 0 | 0.0% |
| IC | 11 | 15.3% | 3 | 20.0% |
| IIA | 4 | 5.6% | 2 | 13.3% |
| IIB | 3 | 4.2% | 1 | 6.7% |
| IIC | 1 | 1.4% | 0 | 0.0% |
| IIIA | 3 | 4.2% | 0 | 0.0% |
| IIIB | 3 | 4.2% | 1 | 6.7% |
| IIIC | 24 | 33.3% | 4 | 26.7% |
| IV | 5 | 6.9% | 3 | 20.0% |
| Unknown | 15 | 20.8% | 1 | 6.7% |
| ECOG Performance status | ||||
| 0 | 47 | 65.3% | 9 | 60.0% |
| 1 | 17 | 23.6% | 5 | 33.3% |
| 2 | 5 | 6.9% | 1 | 6.7% |
| 3 | 3 | 4.2% | 0 | 0.0% |
| Tumor type | ||||
| High grade serous carcinoma | 29 | 38.7% | 10 | 66.7% |
| Low grade serous carcinoma | 3 | 4.0% | 0 | 0.0% |
| Serous carcinoma (Not classified) | 20 | 26.7% | 2 | 13.3% |
| Endometrioid carcinoma | 5 | 6.7% | 1 | 6.7% |
| Adenosarcoma | 5 | 6.7% | 0 | 0.0% |
| Mixed carcinoma | 4 | 5.3% | 0 | 0.0% |
| Clear cell carcinoma | 2 | 2.7% | 0 | 0.0% |
| Carcinosarcoma | 0 | 0.0% | 1 | 6.7% |
| Mucinous carcinoma | 1 | 1.3% | 0 | 0.0% |
| Müllerian mixed tumor | 1 | 1.3% | 0 | 0.0% |
| Serous borderline tumor, micropapillary variant | 1 | 1.3% | 0 | 0.0% |
| Unclassified | 1 | 1.3% | 1 | 6.7% |